TY - JOUR
T1 - Purified human basophils do not generate LTB4
AU - Warner, Jane A.
AU - Freeland, Howard S.
AU - MacGlashan, Donald W.
AU - Lichtenstein, Lawrence M.
AU - Peters, Stephen P.
N1 - Funding Information:
*Supported by National Institutes of Health grants AI 20253, AI 20136, and AI 07290. Publication number 687 from the O’NeilI Laboratories at The Good Samaritan Hospital, 5601 Loch Raven Boulevard, Baltimore, MD 21239. “TAddress all correspondence to: Dr. Donald W. Mac-Glashan, Jr., Division of Clinical Immunology, The Good Samaritan Hospital, 5601 Loch Raven Blvd., Baltimore, MD 21239. *Recipient of a Pfizer Biomedical Research Award.
PY - 1987/10/1
Y1 - 1987/10/1
N2 - We investigated the release of the 5-lipoxygenase derivatives of arachidonic acid (AA) in purified human basophils and compared them with similar results obtained in the human lung mast cell. We have shown that purified basophils (average purity = 51± 6%) challenged with 0.1 μg/ml anti-IgE released histamine (35 ± 9%), and LTC4 (32 ± 10 ng/106 cells) but failed to release measurable quantities of immunoreactive LTB4. In contrast, the non-specific stimulus, A23187, caused the release of histamine and both LTC4 (279 ± 95 ng/106 cells) and LTB4 (148 ± 41 ng/106 cells). Closer analysis of the data revealed an inverse relationship between the levels of LTB4 released and the purity of the basophils, strongly suggesting that the contaminating monocytes were responsible for LTB4 synthesis. Purified human lung mast cells have been shown to release 6 ng of immunoreactive LTB4 106 cells, indicating that basophils release significantly less LTB4 following an IgE-mediated challenge. In a series of experiments using highly purified basophils prelabeled with [3H]AA, we demonstrated that exposure to 0.1 μg/ml anti-IgE led to the release of [3H]LTC4, with no detectable [3H]LTB4, whereas exposure to 1.0 μg/ml A23187 caused the release of [3H]LTC4 and smaller quantities of [3H]LTB4, [3H]LTD4, and [3H]LTE4. We failed to detect any [3H]LTB4 in the cell pellet following challenge with either anti-IgE or A23187, indicating that LTB4 was not synthesized and retained within the cell pellet. Finally, we found that exogenously added [3H]LTB4 was not metabolized, either by basophils alone or by basophils stimulated with anti-IgE (O.1 μg/ml).
AB - We investigated the release of the 5-lipoxygenase derivatives of arachidonic acid (AA) in purified human basophils and compared them with similar results obtained in the human lung mast cell. We have shown that purified basophils (average purity = 51± 6%) challenged with 0.1 μg/ml anti-IgE released histamine (35 ± 9%), and LTC4 (32 ± 10 ng/106 cells) but failed to release measurable quantities of immunoreactive LTB4. In contrast, the non-specific stimulus, A23187, caused the release of histamine and both LTC4 (279 ± 95 ng/106 cells) and LTB4 (148 ± 41 ng/106 cells). Closer analysis of the data revealed an inverse relationship between the levels of LTB4 released and the purity of the basophils, strongly suggesting that the contaminating monocytes were responsible for LTB4 synthesis. Purified human lung mast cells have been shown to release 6 ng of immunoreactive LTB4 106 cells, indicating that basophils release significantly less LTB4 following an IgE-mediated challenge. In a series of experiments using highly purified basophils prelabeled with [3H]AA, we demonstrated that exposure to 0.1 μg/ml anti-IgE led to the release of [3H]LTC4, with no detectable [3H]LTB4, whereas exposure to 1.0 μg/ml A23187 caused the release of [3H]LTC4 and smaller quantities of [3H]LTB4, [3H]LTD4, and [3H]LTE4. We failed to detect any [3H]LTB4 in the cell pellet following challenge with either anti-IgE or A23187, indicating that LTB4 was not synthesized and retained within the cell pellet. Finally, we found that exogenously added [3H]LTB4 was not metabolized, either by basophils alone or by basophils stimulated with anti-IgE (O.1 μg/ml).
UR - http://www.scopus.com/inward/record.url?scp=0023640444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023640444&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(87)90632-0
DO - 10.1016/0006-2952(87)90632-0
M3 - Article
C2 - 2444228
AN - SCOPUS:0023640444
SN - 0006-2952
VL - 36
SP - 3195
EP - 3199
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 19
ER -